Biogen | BIIB - Cost Of Sales


Biogen reported $797.5M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Merck USD 2.94B 380M Mar/2026
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.67B 621M Mar/2026
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026